Cargando…

Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension

BACKGROUND/AIMS: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jae Hyun, Kim, Jung Min, Cho, Youn Zoo, Na, Ji Hoon, Kim, Hyun Sik, Kim, Hyoun A, Kang, Hye Won, Baik, Soon Koo, Kwon, Sang Ok, Cha, Seung Hwan, Kim, Young Ju, Kim, Moon Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278069/
https://www.ncbi.nlm.nih.gov/pubmed/25548744
http://dx.doi.org/10.3350/cmh.2014.20.4.376
_version_ 1782350463295815680
author Kim, Jae Hyun
Kim, Jung Min
Cho, Youn Zoo
Na, Ji Hoon
Kim, Hyun Sik
Kim, Hyoun A
Kang, Hye Won
Baik, Soon Koo
Kwon, Sang Ok
Cha, Seung Hwan
Kim, Young Ju
Kim, Moon Young
author_facet Kim, Jae Hyun
Kim, Jung Min
Cho, Youn Zoo
Na, Ji Hoon
Kim, Hyun Sik
Kim, Hyoun A
Kang, Hye Won
Baik, Soon Koo
Kwon, Sang Ok
Cha, Seung Hwan
Kim, Young Ju
Kim, Moon Young
author_sort Kim, Jae Hyun
collection PubMed
description BACKGROUND/AIMS: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monotherapy on portal pressure in patients with cirrhosis in a prospective, randomized controlled trial. METHODS: Between January 2008 and July 2009, 53 cirrhotic patients with clinically significant portal hypertension were randomized to receive either candesartan and propranolol combination therapy (26 patients) or propranolol monotherapy (27 patients). Before and 3 months after the administration of the planned medication, the hepatic venous pressure gradient (HVPG) was assessed in both groups. The dose of propranolol was subsequently increased from 20 mg bid until the target heart rate was reached, and the candesartan dose was fixed at 8 mg qd. The primary endpoint was the HVPG response rate; patients with an HVPG reduction of >20% of the baseline value or to <12 mmHg were defined as responders. RESULTS: The mean portal pressure declined significantly in both groups, from 16 mmHg (range, 12-28 mmHg) to 13.5 mmHg (range, 6-20 mmHg) in the combination group (P<0.05), and from 17 mmHg (range, 12-27 mmHg) to 14 mmHg (range, 7-25 mmHg) in the propranolol monotherapy group (P<0.05). However, the medication-induced pressure reduction did not differ significantly between the two groups [3.5 mmHg (range, -3-11 mmHg) vs. 3 mmHg (range, -8-10 mmHg), P=0.674]. The response rate (55.6% vs. 61.5%, P=0.435) and the reductions in mean blood pressure or heart rate also did not differ significantly between the combination and monotherapy groups. CONCLUSIONS: The addition of candesartan (an ARB) to propranolol confers no benefit relative to classical propranolol monotherapy for the treatment of portal hypertension, and is thus not recommended.
format Online
Article
Text
id pubmed-4278069
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Korean Association for the Study of the Liver
record_format MEDLINE/PubMed
spelling pubmed-42780692014-12-29 Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension Kim, Jae Hyun Kim, Jung Min Cho, Youn Zoo Na, Ji Hoon Kim, Hyun Sik Kim, Hyoun A Kang, Hye Won Baik, Soon Koo Kwon, Sang Ok Cha, Seung Hwan Kim, Young Ju Kim, Moon Young Clin Mol Hepatol Original Article BACKGROUND/AIMS: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monotherapy on portal pressure in patients with cirrhosis in a prospective, randomized controlled trial. METHODS: Between January 2008 and July 2009, 53 cirrhotic patients with clinically significant portal hypertension were randomized to receive either candesartan and propranolol combination therapy (26 patients) or propranolol monotherapy (27 patients). Before and 3 months after the administration of the planned medication, the hepatic venous pressure gradient (HVPG) was assessed in both groups. The dose of propranolol was subsequently increased from 20 mg bid until the target heart rate was reached, and the candesartan dose was fixed at 8 mg qd. The primary endpoint was the HVPG response rate; patients with an HVPG reduction of >20% of the baseline value or to <12 mmHg were defined as responders. RESULTS: The mean portal pressure declined significantly in both groups, from 16 mmHg (range, 12-28 mmHg) to 13.5 mmHg (range, 6-20 mmHg) in the combination group (P<0.05), and from 17 mmHg (range, 12-27 mmHg) to 14 mmHg (range, 7-25 mmHg) in the propranolol monotherapy group (P<0.05). However, the medication-induced pressure reduction did not differ significantly between the two groups [3.5 mmHg (range, -3-11 mmHg) vs. 3 mmHg (range, -8-10 mmHg), P=0.674]. The response rate (55.6% vs. 61.5%, P=0.435) and the reductions in mean blood pressure or heart rate also did not differ significantly between the combination and monotherapy groups. CONCLUSIONS: The addition of candesartan (an ARB) to propranolol confers no benefit relative to classical propranolol monotherapy for the treatment of portal hypertension, and is thus not recommended. The Korean Association for the Study of the Liver 2014-12 2014-12-24 /pmc/articles/PMC4278069/ /pubmed/25548744 http://dx.doi.org/10.3350/cmh.2014.20.4.376 Text en Copyright © 2014 by The Korean Association for the Study of the Liver http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Jae Hyun
Kim, Jung Min
Cho, Youn Zoo
Na, Ji Hoon
Kim, Hyun Sik
Kim, Hyoun A
Kang, Hye Won
Baik, Soon Koo
Kwon, Sang Ok
Cha, Seung Hwan
Kim, Young Ju
Kim, Moon Young
Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
title Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
title_full Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
title_fullStr Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
title_full_unstemmed Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
title_short Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
title_sort effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278069/
https://www.ncbi.nlm.nih.gov/pubmed/25548744
http://dx.doi.org/10.3350/cmh.2014.20.4.376
work_keys_str_mv AT kimjaehyun effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension
AT kimjungmin effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension
AT choyounzoo effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension
AT najihoon effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension
AT kimhyunsik effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension
AT kimhyouna effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension
AT kanghyewon effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension
AT baiksoonkoo effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension
AT kwonsangok effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension
AT chaseunghwan effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension
AT kimyoungju effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension
AT kimmoonyoung effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension